Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Erectile Dysfunction 2Carcinoma 2Urinary Incontinence 1Pyridoxine-dependent epilepsy 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Paclitaxel 3Amifostine 3Vincristine 2Procarbazine 2haloperidol decanoate 1axicabtagene ciloleucel 1Thalidomide 1Tadalafil 1Surveys and Questionnaires 1SLI381 1Rituximab 1Radiotherapy 1Prednisolone 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Modafinil 1Methylphenidate 1Methotrexate 1Melphalan 1Lorazepam 1Leucovorin 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1Glutamine 1Gene Expression Profiling 1Folfox protocol 1Fluorouracil 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurotoxicity Syndromes × Tadalafil × Clear all
NCT07333976 2026-01-12

o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

Tri-Service General Hospital

Phase 2 Completed
90 enrolled

Peripheral Nervous System Diseases, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡